QR Kodea

Type 2 asthma paediatric patients eligible for dupilumab: An Italian biomarker-based analysis

Background: Type 2 inflammation is the principal determinant of asthma in children, and it leads to the downstream activation of eosinophils (EOS), the production of immunoglobulin-E (IgE), and increased levels of fraction of exhaled nitric oxide (FeNO). Dupilumab received the approval for the treat...

Deskribapen osoa

Gorde:
Egile Nagusiak: Giorgio Piacentini, MD, Alessandro Fiocchi, MD, Gianluigi Marseglia, MD, Michele Miraglia Del Giudice, MD, Renato Cutrera, MD, Rossella Bitonti, MSc, Francesca Fanelli, MSc, Annalisa Stassaldi, MSc, Giuliana Nicolosi, MD, Gianluca Furneri, MSc
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2024-08-01
Saila:World Allergy Organization Journal
Gaiak:
Type 2 asthma
Dupilumab
Biomarker
Italy
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S1939455124000644
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak